Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
News headline image
Seagen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
From Seagen Inc.
Via Business Wire
News headline image
Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021
From Seagen Inc.
Via Business Wire
News headline image
A Look Into Seagen's Price Over Earnings ↗
In the current market session, Seagen Inc. (NASDAQ:SGEN) is trading at $165.17, after a 0.24% drop. However, over the past month, the stock increased by 14.36%, and... 
Via Benzinga
News headline image
Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal ↗
Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to... 
Via Talk Markets
News headline image
Earnings Scheduled For July 29, 2021 ↗
Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter. • Cohen & Co (AMEX:COHN) is... 
Via Benzinga
News headline image
Earnings Scheduled For April 29, 2021 ↗
Companies Reporting Before The Bell • OSI Systems (NASDAQ:OSIS) is estimated to report quarterly earnings at $1.33 per share on revenue of $290.51 million. •... 
Via Benzinga
News headline image
Seagen Bets On China's ADC In $2.6B Cancer Deal ↗
Seagen Inc (NASDAQ: SGEN) and RemeGen Co Ltd have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin... 
Via Benzinga
News headline image
Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin
From Seagen Inc.
Via Business Wire
News headline image
Seattle Genetics (SGEN) Q2 2021 Earnings Call Transcript ↗
SGEN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Seagen Reports Second Quarter 2021 Financial Results
From Seagen Inc.
Via Business Wire
News headline image
Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer ↗
The FDA granted full approval and a label expansion for Seagen Inc (NASDAQ: SGEN) - Astellas Pharma Inc's (OTC: ALPMF) PADCEV to treat... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
News headline image
U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
News headline image
Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2021 Financial Results on July 29, 2021
From Seagen Inc.
Via Business Wire
News headline image
Updated Analysis Show Seagen's Tukysa Extended Median OS to Two Years with Benefits Maintained in Breast Cancer ↗
Seagen Inc (NASDAQ: SGEN) has announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow-up... 
Via Benzinga
News headline image
Seagen Announces Long-Term Results from TUKYSA® (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting
From Seagen Inc.
Via Business Wire
News headline image
Seagen to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
From Seagen Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
News headline image
Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy
From Seagen Inc.
Via Business Wire
News headline image
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows ↗
Although they have been struggling recently, these stocks remain attractive buys over the long term. 
Via The Motley Fool
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
Friday morning saw 14 companies set new 52-week lows. Points of Interest: Lufax Holding (NYSE:LU) was the largest, in terms of market cap, to set a new 52-week low... 
Via Benzinga
News headline image
Seattle Genetics (SGEN) Q1 2021 Earnings Call Transcript ↗
SGEN earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Recap: Seagen Q1 Earnings ↗
Shares of Seagen (NASDAQ:SGEN) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 31.63% over the past year to... 
Via Benzinga
News headline image
Seagen Reports First Quarter 2021 Financial Results
From Seagen Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
News headline image
Seagen to Showcase Data from Growing Oncology Portfolio During Virtual Scientific Program of the 2021 ASCO Annual Meeting
From Seagen Inc.
Via Business Wire
News headline image
Seattle Genetics's Earnings Outlook ↗
Seattle Genetics (NASDAQ:SGEN) announces its next round of earnings this Thursday, April 29. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings... 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx ↗
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.